Loading people...
Kristina Ekberg is a Partner and General Counsel at HealthCap, a European venture capital firm based in Stockholm, Sweden. She officially joined the investment firm's senior leadership team during an expansion in September 2021 to oversee legal operations and structure venture transactions across the biotechnology and pharmaceutical sectors. Prior to her current role, Ekberg spent several years serving as a Partner in the mergers and acquisitions practice group at Vinge, which operates as one of the largest corporate law firms in the Nordic region. During her tenure at Vinge, she directed the firm's Life Sciences and Healthcare sector group, advising institutional clients on complex corporate transactions and regulatory frameworks. Equipped with a Master of Laws degree, Ekberg has built a career that bridges corporate legal strategy and venture investing within the specialized European life sciences market.
Kristina Ekberg stands as a distinguished Partner at HealthCap, a premier European venture capital firm renowned for its strategic investments in the life sciences sector. Her leadership is instrumental in HealthCap's mission to foster groundbreaking innovation in healthcare, particularly within biotechnology, pharmaceuticals, and medical technology.
Dr. Ekberg brings a formidable scientific foundation to her investment acumen. She holds a Ph.D. in Molecular Biology from Uppsala University, a testament to her deep understanding of biological processes at their most fundamental level. Following her doctoral studies, she further honed her research capabilities through postdoctoral work at the prestigious Karolinska Institute, contributing to cutting-edge scientific discovery.
Before transitioning into venture capital, Kristina Ekberg accumulated valuable industry experience. She served as a Senior Scientist at Biovitrum (now Sobi), a biopharmaceutical company, where she gained firsthand insight into drug development and research translation. Her career then progressed to Orexo AB, where she held the position of Director of Business Development, equipping her with critical skills in strategic partnerships, commercialization, and corporate growth within the pharmaceutical landscape.
Joining HealthCap in 2007, Kristina Ekberg quickly became a pivotal member of the investment team. As a Partner, she is deeply involved in all stages of the investment lifecycle, from rigorous due diligence and deal sourcing to active portfolio management. Her investment focus areas are squarely within drug development, advanced biotechnology, and innovative medical technology solutions that address significant unmet medical needs.
Dr. Ekberg's strategic insights and scientific expertise are invaluable to HealthCap's portfolio companies. She has served on the boards of numerous successful ventures, including PledPharma, Wilson Therapeutics, Cantargia, Targovax, and Forendo Pharma, among others. In these roles, she provides critical guidance on scientific strategy, clinical development, business expansion, and fundraising, helping these companies navigate the complex journey from scientific concept to market-ready products. Her work exemplifies HealthCap's commitment to building robust, high-impact life science companies that deliver significant value to patients and investors alike. Kristina Ekberg's dedication to advancing medical innovation underscores her reputation as a leading figure in European life sciences venture capital.
Kristina Ekberg is a highly respected Partner at HealthCap, a leading European venture capital firm specializing in life sciences investments. She is known for her deep scientific background and expertise in guiding innovative biotech and pharmaceutical companies.
As a Partner at HealthCap, Kristina Ekberg primarily invests in companies within the life sciences sector. Her focus areas include drug development, biotechnology, pharmaceuticals, and advanced medical technology solutions.
Kristina Ekberg works as a Partner at HealthCap, a prominent European venture capital firm. HealthCap is dedicated to investing in and developing groundbreaking companies across the life sciences industry.
